Join to View Full Profile
550 17th AveSte 500Seattle, WA 98122
Phone+1 206-320-2800
Fax+1 206-320-3153
Dr. Ludlam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1995 - 1997
Albert Einstein College of MedicineClass of 1995
Certifications & Licensure
OR State Medical License 1998 - Present
WA State Medical License 2007 - 2025
Clinical Trials
- An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Start of enrollment: 2011 Aug 16
Publications & Presentations
PubMed
- 9 citationsDurable biochemical response and safety with oral octreotide capsules in acromegaly.Susan L Samson, Lisa B Nachtigall, Maria Fleseriu, Mojca Jensterle, Patrick J Manning
European Journal of Endocrinology. 2022-12-01 - 18 citationsMaintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised contr...Maria Fleseriu, Alexander Dreval, Irina Bondar, Gulnar Vagapova, Djuro Macut
The Lancet. Diabetes & Endocrinology. 2022-02-01 - 56 citationsMaintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.Susan L. Samson, Lisa B. Nachtigall, Maria Fleseriu, Murray B. Gordon, Marek Bolanowski
The Journal of Clinical Endocrinology and Metabolism. 2020-10-01
Press Mentions
AstraZeneca Promotes Oncology Exec to CMO; Pfizer Replaces Retiring Chief Dealmaker as War Chest ExpandsAugust 27th, 2021- Chutes & Ladders—Pfizer Taps McKinsey U.S. Managing Partner as New M&a LeaderAugust 27th, 2021
- Recordati Rare Diseases Announces William Ludlam, MD, PhD, as New Chief Medical Officer and Vice President - Clinical DevelopmentAugust 25th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
